clinical trial · NCT06352528
A Study to Assess the Drug Levels of Repotrectinib in Healthy Participants and Participants With Moderate and Severe Hepatic Impairment
Bristol-Myers Squibb·phase1·completed·n = 18
Hepatic ImpairmentHealthy VolunteersRepotrectinib
brief summary
The purpose of this study is to assess the drug levels of a single oral dose of repotrectinib in participants with moderate and severe HI, and in healthy matched control participants with normal hepatic function.
started
Apr 29, 2024
primary completion
Sep 16, 2025
completion
Sep 16, 2025
last updated
Oct 6, 2025
official title
A Phase 1, Multicenter, Open-label, Single-dose Study to Assess the Pharmacokinetics of Repotrectinib in Healthy Participants and Those With Moderate and Severe Hepatic Impairment
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol